Navigation Links
VisionGate’s LuCED® Test and New Drug Therapy to Prevent Lung Cancer Demonstrate Promise in National Surveys of Pulmonologists

Two recent surveys conducted by an independent, third-party research group validated the market demand for VisionGate’s LuCED test as well as its recently licensed drug therapy, Iloprost, in the diagnosis and treatment of patients at risk of lung cancer.

LuCED, represented as “Product X” in surveys among 100 pulmonologists, is a non-invasive test to aid in the early detection of lung cancer. To date, LuCED has also demonstrated the ability to detect dysplasia, a condition that often precedes lung cancer. The results of the survey showed that 60 percent of pulmonologists would use VisionGate’s LuCED test today based on current clinical evidence. Reasons cited included LuCED’s current sensitivity (92-95 percent for early stage lung cancer) and specificity (99 percent), avoidance of radiation, convenience and the non-invasive method of testing.

With regard to use, 38 percent of physicians would use LuCED as the primary screening tool if it were available today (and reimbursement was available); 30 percent would screen all patients with both low-dose CT scans (LDCT) and LuCED, 24 percent would give patients the option of using either LDCT or LuCED and 8 percent would continue to use LDCT as the primary screening tool.

Another area of interest among the pulmonologists surveyed was preventative medicine, or chemoprevention drug therapies that help reverse the disease process before it advances to life-threatening cancer.

In January, VisionGate announced it had acquired exclusive rights to the chemoprevention drug Iloprost. Overall, 72 percent of the pulmonologists surveyed found Iloprost attractive in the future treatment of endobronchial dysplasia.

Furthermore, assuming both Iloprost and reimbursement were available today, respondents would use oral Iloprost as a chemoprevention agent for 50 percent of their CMS-defined, high-risk patients with dysplasia, 50 percent of other high-risk patients and 48 percent of lung cancer survivor patients with dysplasia.

“The survey results confirm what we had anticipated – that the LuCED diagnostic test combined with our Iloprost drug therapy will deliver a much-needed impact in the standard of care for lung cancer,” VisionGate Founder and CEO Alan Nelson, PhD, said. “The optimism from the pulmonologist community demonstrates their commitment to early detection and an openness to our test + treat (Dx/Rx) model.”

For more information, visit


About VisionGate

VisionGate, Inc. is led by Dr. Alan Nelson, physicist, bioengineer and entrepreneur who previously developed the world’s first and only automated screening test to detect cervical cancer, marketed globally today as FocalPoint by Becton Dickinson. VisionGate’s proprietary LuCED test is a non-invasive diagnostic test for early-stage lung cancer, demonstrating exquisite sensitivity and specificity in blinded clinical studies. This physician-ordered, take-home sputum test is processed on the world’s first automated 3D cell imaging platform, the Cell-CT, named aptly because it is similar in principle to taking a CT scan of individual cells, but using visible light without harmful radiation. Moreover, with the new exclusive patent license from the University of Colorado for the drug called Iloprost, VisionGate will drive the therapeutic market for chemoprevention of lung cancer and, ultimately, the eradication of this killer. With 145 issued patents in 13 countries, VisionGate expects to play a leading role in the battle against the world’s number one cancer killer.

Read the full story at

Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved

Related medicine news :

1. VisionGate’s Alan Nelson Named National Academy of Inventors Fellow
2. The Economist honors cancer immunotherapy pioneer James Allison
3. Revisiting Prevention of Blood Clots in Chemotherapy Patients
4. Yogafit Partners With Wholebeing Institute, Bringing Positive Psychology Into Yoga Therapy Training
5. Hands On HealthCare Massage Therapy and Wellness Day Spa Of Long Island Announces Early Black Friday and Cyber Monday Specials
6. Tailored pre-transplant therapy boosts survival rate in rare immune deficiency
7. Biomaterial-delivered chemotherapy could provide final blow to brain tumors
8. Clinical trial looks at impact of platelet-rich plasma therapy on tennis elbow
9. LSUHSCs Rodriguez receives cancer immunotherapy Presidential Award
10. Athletico Physical Therapy Selected as #1 Workplace by Chicago Tribune
11. Clinical trial finds concurrent therapy not necessary to achieve high pathological in breast cancer
Post Your Comments:
(Date:12/6/2019)... ... December 06, 2019 , ... ... frequently, six students in Salt Lake Community College’s (SLCC) Emergency Medical ... Rodgers and Chelise Schaefer—were awarded the AT&T Public Safety Hero Scholarship to support ...
(Date:12/6/2019)... (PRWEB) , ... December 06, 2019 , ... ... symposium for healthcare professionals in Baltimore, Maryland at the AES Annual Meeting. The ... learning objectives: , 1. Understand methods of quantitative sEMG analysis during ictal events;, ...
(Date:12/5/2019)... MATEO, Calif. (PRWEB) , ... December 05, 2019 , ... ... fall asleep over 25 million times this year using Bible-based bedtime stories. Listeners have ... refreshed minds. , According to the Center for Disease Control, one third of Americans ...
(Date:12/5/2019)... ... 05, 2019 , ... Today at M Health Fairview University of ... member who will to help them take medicine, relax during anxious moments, encourage ... Rocket, presented by NutriSource® is a golden retriever and the first and only ...
(Date:12/4/2019)... ... , ... Healthcare Real Estate Insights™ magazine has announced the ... recognizing excellence in the areas of healthcare real estate (HRE) development and executive ... the GlobeSt Healthcare Conference today in Scottsdale, Ariz. , The awards are presented ...
Breaking Medicine News(10 mins):
(Date:12/6/2019)... Wis. (PRWEB) , ... December 06, 2019 , ... ... USP 800, targeted for implementation this month, Kenall is introducing the CSEDOIC luminaire ... tightly controlled. USP 800 now requires the unpacking of hazardous drugs (HDs) and ...
(Date:12/6/2019)... ... 2019 , ... The Multiple System Atrophy Coalition (MSA Coalition), ... initiative to kickstart MSA research collaborations. Multiple system atrophy is a rare ... million in new bequests earmarked for research and combined with ongoing grassroots fundraising ...
(Date:12/5/2019)... ... December 05, 2019 , ... LeadingBiotech ,?an exclusive ... announces key issues to be discussed at its East/West CEO conference ... in San Francisco. , Kicking off the week of the J.P. ...
Breaking Medicine Technology: